Home Cart Sign in  
Chemical Structure| 946128-88-7 Chemical Structure| 946128-88-7

Structure of Avutometinib
CAS No.: 946128-88-7

Chemical Structure| 946128-88-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Avutometinib (Ro 5126766) is a dual MEK/RAF inhibitor with anti-tumor activity. It inhibits BRAFV600E, CRAF, MEK, and BRAF with IC50 values of 8.2 nM, 56 nM, 160 nM, and 190 nM, respectively.

Synonyms: CH5126766; Ro 5126766

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Avutometinib

CAS No. :946128-88-7
Formula : C21H18FN5O5S
M.W : 471.46
SMILES Code : O=S(NC)(NC1=NC=CC(CC2=C(C)C3=CC=C(OC4=NC=CC=N4)C=C3OC2=O)=C1F)=O
Synonyms :
CH5126766; Ro 5126766
MDL No. :MFCD27987901

Safety of Avutometinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Avutometinib

MAPK

Isoform Comparison

Biological Activity

Target
  • B-Raf

    BRAF V600E, IC50:8.2 nM

    BRAF, IC50:19 nM

  • C-Raf/Raf-1

    CRAF, IC50:56 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
YUMM3.2;Pten-/-;Akt1E17K cells 600 nM 72 hours To evaluate the effect of avutometinib alone or in combination with VS-4718 on cell viability, the combination significantly reduced cell viability PMC11866499
YUMM3.2;Pten-/-;Akt1E17K cells 256 nM 72 hours To evaluate the effect of RAF/MEK inhibition on melanoma cell proliferation, results showed avutometinib significantly inhibited cell proliferation at concentrations ≥625 nM PMC11866499
Primary uterine endometrioid cell lines 0.001, 0.01, 0.1, 1, 10 μM 72 hours Evaluate cell viability, IC50 of avutometinib for UTE11 was 7.5 ± 1.2 μM PMC11378359

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Subcutaneous allograft model of YUMM3.2;Pten-/-;Akt1E17K cells Oral 0.3 mg/kg Once daily for 28 days To evaluate the effect of avutometinib alone or in combination with VS-4718 on established primary melanoma tumor growth, the combination resulted in tumor regression and significantly prolonged survival PMC11866499
CB17/lcrHsd-Prkdc/SCID mice UTE10 xenograft model Oral gavage 0.3 mg/kg avutometinib and 50 mg/kg VS-4718 Five consecutive days of treatment with 2 days of rest, until tumor volume reached 1 cm3 Evaluate antitumor activity of avutometinib and VS-4718 alone and in combination, combination treatment significantly inhibited tumor growth and prolonged survival PMC11378359
Mice NCI-H1435 tumor xenograft model Oral gavage 0.3 mg/kg BID Q2D Twice daily for 7 days Evaluated the effect of Avutometinib on KRAS-MAPK pathway signaling, showing a significant 85% reduction in pERK levels PMC11443210
Nude mice YUMM4.1 NF1-KO xenograft model Oral Avutometinib 1.5 mg/kg, BI-3406 50 mg/kg Avutometinib 3 times a week, BI-3406 BID, for 70 days To evaluate the inhibitory effect of combined MEK and SOS1 inhibition on NF1-null tumor growth PMC11604403

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT06104488 Refractory Cancer|CNS Tumors|C... More >>NS Tumor, Adult|CNS Tumor, Childhood|MAP Kinase Family Gene Mutation|NF1|Plexiform Neurofibroma|Low-grade Glioma|Optic Pathway Gliomas|Neuroblastoma|Primary Brain Tumor|Solid Tumor|Solid Tumor, Adult|Solid Carcinoma|Central Nervous System Tumor Less << PHASE1 RECRUITING 2029-10-20 Children's Healthcare of Atlan... More >>ta (Data Collection Only), Atlanta, Georgia, 30322, United States|Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, 10065, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.12mL

0.42mL

0.21mL

10.61mL

2.12mL

1.06mL

21.21mL

4.24mL

2.12mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories